» Articles » PMID: 2502439

Improved Pregnancy Outcome with the Addition of Leuprolide Acetate to Gonadotropins for in Vitro Fertilization

Overview
Journal Fertil Steril
Date 1989 Aug 1
PMID 2502439
Citations 6
Authors
Affiliations
Soon will be listed here.
Abstract

In vitro fertilization treatment outcomes were compared prospectively in unselected patients with and without the addition of leuprolide acetate to gonadotropins for ovarian hyperstimulation. While the leuprolide patients required greater quantities of exogenous gonadotropins to achieve ovarian stimulation, significant improvements in the fertilization, implantation, and spontaneous abortion rates were observed compared with patients not receiving leuprolide. The ongoing pregnancy ("take home baby") rates per aspiration with and without leuprolide were 29% and 12%, respectively. Furthermore, the multiple pregnancy rate was markedly increased in the leuprolide group (44% versus 8%), suggesting that the improved pregnancy outcome with pituitary suppression was due primarily to higher oocyte and embryo quality.

Citing Articles

The effects of gonadotropin-releasing hormone agonist on androstenedione production and follicular development during controlled ovarian hyperstimulation.

Akaboshi K, Oda T, Yoshida J, Kohriyama S, Miyazaki T, Yoshimura Y J Assist Reprod Genet. 1998; 15(8):478-84.

PMID: 9785195 PMC: 3455046. DOI: 10.1023/a:1022530420110.


Elevated serum progesterone values at the time of ovulation induction in luteal leuprolide acetate-down-regulated GIFT cycles are associated with decreased clinical pregnancy rates.

Randall G, Gantt P, Gantt D, Kirk M, Romines N J Assist Reprod Genet. 1996; 13(6):459-63.

PMID: 8835672 DOI: 10.1007/BF02066524.


Gonadotrophin-releasing hormone agonists. A guide to use and selection.

Filicori M Drugs. 1994; 48(1):41-58.

PMID: 7525194 DOI: 10.2165/00003495-199448010-00005.


Ovarian stimulation with gonadotropin-releasing hormone (GnRH) analogue improves the in vitro fertilization (IVF) pregnancy rate with both transvaginal and laparoscopic oocyte recovery.

Dor J, Ben-Shlomo I, Lipitz S, Levran D, Etchin A, Rudak E J In Vitro Fert Embryo Transf. 1990; 7(6):351-4.

PMID: 2150203 DOI: 10.1007/BF01130589.


The use of gonadotropin releasing hormone agonist (GnRHa) in good responders undergoing repeat in vitro fertilization/embryo transfer (IVF/ET).

Segars J, Hill G, Bryan S, Herbert 3rd C, Osteen K, Rogers B J In Vitro Fert Embryo Transf. 1990; 7(6):327-31.

PMID: 2127603 DOI: 10.1007/BF01130584.